Biocardia Valuation

BCDA Stock  USD 1.32  0.03  2.22%   
Today, the firm appears to be undervalued. Biocardia shows a prevailing Real Value of $4.82 per share. The current price of the firm is $1.32. Our model approximates the value of Biocardia from analyzing the firm fundamentals such as Current Valuation of 9.68 M, return on equity of -3.17, and Shares Owned By Insiders of 26.66 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Biocardia's valuation include:
Price Book
5.4538
Enterprise Value
9.7 M
Enterprise Value Ebitda
(3.16)
Price Sales
3.1 K
Enterprise Value Revenue
3.1 K
Undervalued
Today
1.32
Please note that Biocardia's price fluctuation is moderately volatile at this time. Calculation of the real value of Biocardia is based on 3 months time horizon. Increasing Biocardia's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biocardia is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biocardia Stock. However, Biocardia's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  1.32 Real  4.82 Target  15.5 Hype  1.17 Naive  1.24
The real value of Biocardia Stock, also known as its intrinsic value, is the underlying worth of Biocardia Company, which is reflected in its stock price. It is based on Biocardia's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Biocardia's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
4.82
Real Value
8.34
Upside
Estimating the potential upside or downside of Biocardia helps investors to forecast how Biocardia stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biocardia more accurately as focusing exclusively on Biocardia's fundamentals will not take into account other important factors:
Earnings
Estimates
LowProjectedHigh
-0.31-0.31-0.31
Details
Hype
Prediction
LowEstimatedHigh
0.061.174.69
Details
Naive
Forecast
LowNext ValueHigh
0.021.244.77
Details
1 Analysts
Consensus
LowTarget PriceHigh
14.1115.5017.21
Details
Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Biocardia's intrinsic value based on its ongoing forecasts of Biocardia's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Biocardia's closest peers. If more than one evaluation category is relevant for Biocardia we suggest using both methods to arrive at a better estimate.

Biocardia Cash

2.59 Million

Biocardia Total Value Analysis

Biocardia is currently forecasted to have valuation of 9.68 M with market capitalization of 14.33 M, debt of 951 K, and cash on hands of 8.61 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biocardia fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
9.68 M
14.33 M
951 K
8.61 M

Biocardia Investor Information

About 27.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.42. Biocardia last dividend was issued on the 6th of June 2019. The entity had 1:15 split on the 30th of May 2024. Based on the key measurements obtained from Biocardia's financial statements, Biocardia is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.

Biocardia Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biocardia has an asset utilization ratio of 1.56 percent. This suggests that the Company is making $0.0156 for each dollar of assets. An increasing asset utilization means that Biocardia is more efficient with each dollar of assets it utilizes for everyday operations.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

Biocardia Profitability Analysis

Based on the key profitability measurements obtained from Biocardia's financial statements, Biocardia may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in February. Profitability indicators assess Biocardia's ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
1997-03-31
Previous Quarter
-2 M
Current Value
-1.5 M
Quarterly Volatility
2.4 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
The current year's Gross Profit is expected to grow to about (3.7 M). The current year's Pretax Profit Margin is expected to grow to -26.5
For Biocardia profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Biocardia to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Biocardia utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Biocardia's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Biocardia over time as well as its relative position and ranking within its peers.

Biocardia Earnings per Share Projection vs Actual

By analyzing Biocardia's earnings estimates, investors can diagnose different trends across Biocardia's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Biocardia is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
 
Interest Hikes
Biocardia is projected to generate -0.3125 in earnings per share on the 31st of December 2025. Biocardia earnings estimates show analyst consensus about projected Biocardia EPS (Earning Per Share). It derives the highest and the lowest estimates based on Biocardia's historical volatility. Many public companies, such as Biocardia, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

Biocardia Ownership Allocation

The market capitalization of Biocardia is $14.33 Million. Biocardia retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Biocardia Profitability Analysis

The company reported the previous year's revenue of 58 K. Net Loss for the year was (7.95 M) with loss before overhead, payroll, taxes, and interest of (5.25 M).
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Biocardia's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Biocardia and how it compares across the competition.

About Biocardia Valuation

The stock valuation mechanism determines Biocardia's current worth on a weekly basis. Our valuation model uses a comparative analysis of Biocardia. We calculate exposure to Biocardia's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biocardia's related companies.
Last ReportedProjected for Next Year
Gross Profit-3.9 M-3.7 M
Pretax Profit Margin(27.90)(26.50)
Operating Profit Margin(158.64)(150.71)
Net Loss(27.90)(26.50)
Gross Profit Margin(85.83)(81.54)

Biocardia Current Valuation Indicators

Valuation refers to the process of determining the present value of Biocardia and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Biocardia we look at many different elements of the entity such as Biocardia's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Biocardia, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Biocardia's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Biocardia's worth.

Complementary Tools for Biocardia Stock analysis

When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Stocks Directory
Find actively traded stocks across global markets
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world